MOLM-16 Cells
USD 500.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Información general
| Descripción | MOLM-16 is a human leukemia cell line derived from the peripheral blood of an adult woman with minimally differentiated acute myeloid leukemia (AML-M0) at relapse. This line exhibits a distinctive immunophenotype consistent with a myeloid/natural killer (NK) precursor leukemia, expressing CD7, CD13, CD33, CD34, and CD56. Additionally, it displays features of megakaryocytic differentiation, evidenced by the expression of markers such as CD41, CD61, CD36, CD62P, CD110, CD151, thrombospondin, von Willebrand factor (vWF), and fibrinogen. The presence of platelet peroxidase in the nuclear envelope, observed by electron microscopy, further confirms its megakaryoblastic lineage characteristics. MOLM-16 demonstrates cytokine-dependent growth and responds to a range of hematopoietic growth factors including erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), PIXY321, and thrombopoietin (TPO). Cytogenetic analysis reveals complex karyotypic abnormalities such as t(6;8)(q21;q24.3) and t(9;18)(q13;q21), indicating genomic instability common in acute leukemia. The cell line lacks expression of T- and B-lymphoid markers, consistent with its myeloid/NK precursor profile, and is negative for myeloperoxidase (MPO) activity, a hallmark of AML-M0. Due to its unique combination of myeloid, NK, and megakaryocytic features, MOLM-16 serves as a valuable in vitro model for investigating the biology of minimally differentiated AML, megakaryopoiesis, and leukemic differentiation pathways. |
|---|---|
| Organismo | Human |
| Tejido | Peripheral blood |
| Enfermedad | Adult acute myeloid leukemia |
| Sinónimos | MOLM16 |
Características
| Edad | 77 years |
|---|---|
| Género | Female |
| Origen étnico | Japanese |
| Tipo de célula | Epithelial like |
| Propiedades de crecimiento | Suspension |
Datos normativos
| Referencia | MOLM-16 (Cytion catalog number 305831) |
|---|---|
| Nivel de bioseguridad | 1 |
| NCBI_TaxID | 9606 |
| N.º de acceso de Cellosaurus | CVCL_2120 |
Datos biomoleculares
| Perfil mutacional | Mutation: TP53, Simple, p.Val173Met (c.517G>A), Heterozygous (Cosmic-CLP=1330948), TP53, Simple, p.Cys238Ser (c.713G>C), Heterozygous (Cosmic-CLP=1330948) |
|---|
Manejo
| Medio de cultivo | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suplementos | Supplement the medium with 10% FBS |
| Reactivo de disociación | Accutase |
| Tiempo de duplicación | ca. 50-80 hours |
| Densidad de siembra | 1 to 3 x 104 cells/cm2 |
| Renovación de fluidos | 2 to 3 times per week |
| Medio de congelación | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Descongelación y cultivo de células |
|
| Atmósfera de incubación | 37°C, 5% CO2, humidified atmosphere. |
| Condiciones de envío | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Condiciones de almacenamiento | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Control de calidad y análisis molecular
| Esterilidad | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificado de análisis (CoA)
| Número de lote | Tipo de certificado | Fecha | Número de catálogo |
|---|---|---|---|
| 305831-160326 | Certificado de análisis | 04. May. 2026 | 305831 |